Panelists engaged in a debate regarding using complement inhibitors in geographic atrophy, gauging public sentiment with a deciding vote.
|Articles|September 1, 1996
The American Journal of Managed Care
- September 1996
- Volume 2
- Issue 8
The Economic Organization of Health Resource Allocation: Decision Making in the New Environment
Author(s)Douglas L. Cocks, PhD, Thomas W. Croghan, MD
Advertisement
Articles in this issue
about 30 years ago
Potential Cost-Effectiveness of Acute Stroke Treatmentabout 30 years ago
Potential for SSRIs as Monotherapy for Comorbid Psychiatric Disordersabout 30 years ago
Establishing the Basis for Successful Disease Management Contractingabout 30 years ago
Accreditation Standards in Managed Careabout 30 years ago
A Closer Look at CapitationAdvertisement
Related to this article
A session at AAO 2026 highlighted how big data and minimally invasive glaucoma surgery (MIGS) could be utilized to help patients receive peak care.
The opening session of AAO 2026 featured a keynote speech discussing how artificial intelligence (AI) will play a part in health care.
Incidence of diabetic macular edema and the need for glaucoma surgery were reduced after treatment with glucagon-like peptide-1 receptor agonists.
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
TP53 mutations occurred in 3% of myeloproliferative neoplasms (MPNs) but 10% of myelofibrosis or blast-phase cohorts in a review of 11 cohort studies.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Cepheid's Connie Savor, MD, MBA, explains where its 13-pathogen respiratory panel fits in diagnostic stewardship and antibiotic decisions.
Advertisement
Advertisement
Trending on AJMC
1
MASH Fibrosis, Not Resolution, Predicts Mortality: Zobair Younossi, MD
2
Keynote Address Tackles AI’s Role in Health Care, Eye Care
3
Full POLARGO Data Reveal OS, Safety for Pola-R-GemOx in DLBCL
4
FDA Approves Once-Monthly Subcutaneous Olanzapine for Schizophrenia
5